Literature DB >> 11024424

Transcorneal oxygen therapy for glaucoma associated with sickle cell hyphema.

J D Benner1.   

Abstract

PURPOSE: To study three patients with glaucoma caused by sickle cell hyphema who were successfully treated with transcorneal oxygen therapy.
METHODS: Case reports. Three patients with increased intraocular pressure caused by sickle cell hyphema were administered transcorneal oxygen therapy using humidified oxygen at a flow rate that ranged from 1 to 3 l/minute.
RESULTS: All three patients had a dramatic reduction in their intraocular pressure within hours of receiving oxygen therapy. No complications were associated with the oxygen therapy.
CONCLUSION: Transcorneal oxygen therapy can reduce intraocular pressure in patients with glaucoma from sickle cell hyphema. Further study is warranted to evaluate this new therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11024424     DOI: 10.1016/s0002-9394(00)00578-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

Review 1.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

2.  Oxygen Tension in the Aqueous Humor of Human Eyes under Different Oxygenation Conditions.

Authors:  Farideh Sharifipour; Esmaeil Idani; Mitra Zamani; Toktam Helmi; Bahman Cheraghian
Journal:  J Ophthalmic Vis Res       Date:  2013-04

3.  The injection of air/oxygen bubble into the anterior chamber of rabbits as a treatment for hyphema in patients with sickle cell disease.

Authors:  Emre Ayintap; Uğurcan Keskin; Fariz Sadigov; Mesut Coskun; Nilufer Ilhan; Sedat Motor; Hilal Semiz; Nihan Parlakfikirer
Journal:  J Ophthalmol       Date:  2014-04-07       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.